Genflow Biosciences Plc (GB:GENF)
LSE:GENF
Want to see GB:GENF full AI Analyst Report?
GENF Stock Chart & Stats
2.25 p
-0.02 p(-1.09%)
At close: 4:00 PM EST
2.25 p
-0.02 p(-1.09%)
Day’s Range― - ―
52-Week Range0.55 p - 3.12 p
Previous CloseN/A
Volume13.76K
Average Volume (3M)1.73M
Market Cap
£11.61M
Enterprise Value11.33M
Total Cash (Recent Filing)£279.44K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding566,409,800
10 Day Avg. Volume2,042,393
30 Day Avg. Volume1,733,703
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-14.33
Price to Sales (P/S)0.00
P/FCF Ratio-5.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Financial DebtHaving no financial debt materially reduces refinancing and interest-rate risk, preserving flexibility for a cash-burning R&D business. Over a 2–6 month horizon this lowers near-term insolvency risk and gives management optionality to choose equity, partnering or milestone-based funding.
Improving Cash Flow TrendAn improvement in free cash flow implies better cash discipline or milestone progress, which can extend runway and reduce immediate funding needs. While still negative, a demonstrable improvement supports funding conversations and reduces short-term execution risk over the coming months.
Focused R&D In Ageing BiologyConcentrated expertise in gene-based ageing biology targets a large, structural market driven by demographic ageing and chronic disease demand. A clear scientific niche and platform focus can enable durable competitive advantage, strategic partnerships, and premium pricing if clinical translation succeeds.
Bears Say
Pre-Revenue, Persistent LossesBeing pre-revenue with recurring operating losses and negative gross profit means the business relies entirely on external capital to progress R&D. Over months this elevates execution and dilution risk, constrains strategic choices, and forces prioritisation of programs based on funding availability rather than scientific merit.
Negative Shareholders' EquityNegative equity signals accumulated losses have overwhelmed the capital base, undermining balance-sheet resilience. This structural weakness can deter collaborators, impair negotiating leverage, and make future capital raises more dilutive or conditional, raising long-term financing and execution risk.
Weak Cash Generation; Funding DependenceConsistently negative operating cash flow and reliance on external funding create a persistent financing overhang. Sustained dependency increases the likelihood of equity dilution or program delays if markets or partners are unwilling to fund, posing a durable constraint on pipeline progress and commercialization timelines.
Genflow Biosciences Plc News
GENF FAQ
What was Genflow Biosciences Plc’s price range in the past 12 months?
Genflow Biosciences Plc lowest share price was 0.55 p and its highest was 3.12 p in the past 12 months.
What is Genflow Biosciences Plc’s market cap?
Genflow Biosciences Plc’s market cap is £11.61M.
When is Genflow Biosciences Plc’s upcoming earnings report date?
Genflow Biosciences Plc’s upcoming earnings report date is Sep 25, 2026 which is in 117 days.
How were Genflow Biosciences Plc’s earnings last quarter?
Genflow Biosciences Plc released its earnings results on Apr 30, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Genflow Biosciences Plc overvalued?
According to Wall Street analysts Genflow Biosciences Plc’s price is currently Overvalued.
Does Genflow Biosciences Plc pay dividends?
Genflow Biosciences Plc does not currently pay dividends.
What is Genflow Biosciences Plc’s EPS estimate?
Genflow Biosciences Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genflow Biosciences Plc have?
Genflow Biosciences Plc has 566,409,800 shares outstanding.
What happened to Genflow Biosciences Plc’s price movement after its last earnings report?
Genflow Biosciences Plc reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.071%.
Which hedge fund is a major shareholder of Genflow Biosciences Plc?
Currently, no hedge funds are holding shares in GB:GENF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genflow Biosciences Plc
Genflow Biosciences plc operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing or halting the ageing process, and reducing the incidence of age-related diseases with increase in health span. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. The company was incorporated in 2021 and is headquartered in London, the United Kingdom.
Technical Analysis
Oxford BioDynamics
―
Physiomics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---